Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2012
This article has no abstract
Epistemonikos ID: 5d92b86a6cbb551ce311b43f850aa4b5f4899239
First added on: Feb 05, 2025